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Murine leukemia virus-derived retroviral vectors made in murine packaging cell lines are used for hematopoietic cell and other clinical gene therapy protocols. 1 However, low efficiency of gene transfer remains a major limitation for clinical gene therapy. In clinical protocols retrovirus transduction is frequently done ex vivo in the presence of autologous sera or in some instances the packaging cells themselves have been delivered in vivo and exposed to human serum. 2, 3 Complement and ␣-galactosyl natural antibody in human serum can lyse both the murine packaging cell line, as well as derived retrovirus vector, 4 by complement 4, 5 and/or antibody-mediated mechanisms. 3, 6 It is reasonable to assume that improvement of viral stability may contribute to a higher efficiency of gene transfer, though other factors like the concentrations of serum and the polycation polybrene used for transduction, 7 and the presence of unaddressed intracytoplasmic blocks to reverse transcription of retroviral RNA in hematological cells 8, 9 may also contribute to the final efficiency of gene transfer. The problem of retrovirus vector and or packaging cell line inactivation by human serum has been approached in various ways. These include development of complement-resistant vectors, [10] [11] [12] packaging cell lines 3, 13 15 We compare the effect of exposure of retrovirus vector to umbilical cord serum or adult serum on the retrovirus transduction efficiency and show that the retrovirus inactivation is greatly reduced in umbilical cord serum.
The stability and infection efficiency of CRIP/BAG a murine packaging cell line-derived amphotropic retrovirus vector expressing the ␤-galactosidase gene (␤-gal) was examined after pre-incubation of retrovirus vector in adult serum (AS) and umbilical cord serum (CS) ( Figure  1a -c). We found that a 30-min exposure of CRIP/BAG vector to AS inactivated it almost completely (Ͼ95%). In contrast, replacement of AS by CS did not reduce transduction efficiency at 30 min of incubation ( Figure 1a ). This suggested that the mechanisms responsible for inactivation [4] [5] [6] of retrovirus vector in AS were not active in CS. We next studied the possible role of the anti-␣-galactosyl antibody-mediated inactivation of retrovirus vector in CS. Previous work 6 has shown that the addition of galactose ␣1-3galactose to adult serum blocks the anti-␣-galactosyl antibody-mediated inactivation of retrovirus vector. We could confirm this observation since galactose ␣1-3galactose significantly improved retrovirus vector stability in AS (Figure 1a and b) but had no effect on retrovirus vector stability in CS. As compared with the initial transduction efficiency at time 0 min, the transduc- tion efficiency decreased a small amount in anti-␣-galactosyl antibody blocked AS at 30 min (Figure 1b ; P = 0.015, Student's paired two tailed t test). While we have not directly compared the levels of anti-␣-galactosyl antibodies in AS and CS, the high stability of retrovirus vector in CS may be due to the absence or low levels of anti-␣-galactosyl antibodies in CS. This is likely since the fetus does not produce its own antibodies until 6 months of age and any antibodies in CS are likely to be maternal in origin. To evaluate the contribution of complementmediated retroviral inactivation, we heat inactivated sera to destroy complement activity and performed the experiments described in Figure 1a and c. These suggested that complement-mediated inactivation of retrovirus vector did not occur to a significant extent in CS, even though total complement activity (CH 100) is similar in AS and CS (Table 1 ). Also, C1q complement which initiates the complement cascade and inactivates retrovirus vector in an antibody-independent manner 16, 17 by binding to the envelope protein 18 p15E was not significantly different in AS and CS (Table 1) . Other complement pathway components such as C3 and C4 were however higher in AS as compared with CS. These results taken together suggest that the complement and anti-␣-galactosyl antibody-mediated mechanisms that are active in adults are only minimally functional in cord serum of newborns. Infact, the anti-␣-galactosyl natural antibody-mediated mechanism provides a barrier and impediment for the horizontal transmission of retrovirus to humans from non-primate species. 6, 13 Murine retroviruses and packaging cell lines have also a higher stability in cerebrospinal fluid as compared with human serum and it has been postulated that this may allow a higher efficiency of gene transfer in the central nervous system. 19, 20 While it may be argued that retrovirus vector stability can also be maintained by using heat-inactivated AS, the use of CS probably provides many as yet uncharacterized growth factors that may be crucial for optimal replication and differentiation of primitive hematopoietic cells. Our results have important implications for hematopoietic cell and other gene transfer in newborns 21 since they suggest that exposure of retrovirus vector to serum ex vivo or in vivo is not a concern during the first few months of life due to the absence of fetusderived anti-␣-galactosyl natural antibodies.
Figure 1 Transduction efficiency of CRIP/BAG retrovirus vector following incubation in adult serum (AS) or umbilical cord blood serum (CS). Retrovirus packaging cell line CRIP, producing the CRIP/BAG retrovirus was grown to 80-90% confluency in DMEM media

(a) Retrovirus transduction efficiency following exposure to AS (open bars) or CS (closed bars). (b) Effect of anti-␣-galactosyl antibody blockage by addition of galactose ␣1-3galactose (5 mg/ml) to AS (open bars) or CS (closed bars). (c) Vector titer following incubation with heat-inactivated AS (open bars) or CS (closed bars). (d)
